Abstract

While macrophage phagocytosis is an immune defense mechanism against invading cellular organisms, cancer cells expressing the CD47 ligand send forward signals to repel this engulfment. Here we report that the reverse signaling using CD47 as a receptor additionally enhances a pro-survival function of prostate cancer cells under phagocytic attack. Although low CD47-expressing cancer cells still allow phagocytosis, the reverse signaling delays the process, leading to incomplete digestion of the entrapped cells and subsequent tumor hybrid cell (THC) formation. Viable THCs acquire c-Myc from parental cancer cells to upregulate both M1- and M2-like macrophage polarization genes. Consequently, THCs imitating dual macrophage features can confound immunosurveillance, gaining survival advantage in the host. Furthermore, these cells intrinsically express low levels of androgen receptor and its targets, resembling an adenocarcinoma-immune subtype of metastatic castration-resistant prostate cancer. Therefore, phagocytosis-generated THCs may represent a potential target for treating the disease.

The CD47/SIRPα axis is well known to mediate immune escape by promoting cancer resistance to phagocytosis. Here the authors show that low CD47-expressing prostate cancer cells still allow phagocytosis but the process is incomplete leading to the formation of macrophage:tumor hybrid cells with immune evasive and pro-metastatic properties.

Details

Title
Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination
Author
Chou, Chih-Wei 1   VIAFID ORCID Logo  ; Hung, Chia-Nung 1 ; Chiu, Cheryl Hsiang-Ling 1   VIAFID ORCID Logo  ; Tan, Xi 1   VIAFID ORCID Logo  ; Chen, Meizhen 1 ; Chen, Chien-Chin 2   VIAFID ORCID Logo  ; Saeed, Moawiz 1   VIAFID ORCID Logo  ; Hsu, Che-Wei 3 ; Liss, Michael A. 4   VIAFID ORCID Logo  ; Wang, Chiou-Miin 1   VIAFID ORCID Logo  ; Lai, Zhao 1 ; Alvarez, Nathaniel 1   VIAFID ORCID Logo  ; Osmulski, Pawel A. 1   VIAFID ORCID Logo  ; Gaczynska, Maria E. 1   VIAFID ORCID Logo  ; Lin, Li-Ling 1   VIAFID ORCID Logo  ; Ortega, Veronica 5 ; Kirma, Nameer B. 1 ; Xu, Kexin 1   VIAFID ORCID Logo  ; Liu, Zhijie 1   VIAFID ORCID Logo  ; Kumar, Addanki P. 6   VIAFID ORCID Logo  ; Taverna, Josephine A. 7 ; Velagaleti, Gopalrao V. N. 5   VIAFID ORCID Logo  ; Chen, Chun-Liang 8   VIAFID ORCID Logo  ; Zhang, Zhao 1   VIAFID ORCID Logo  ; Huang, Tim Hui-Ming 9   VIAFID ORCID Logo 

 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8) 
 Ditmanson Medical Foundation Chia-Yi Christian Hospital, Department of Pathology, Chiayi, Taiwan (GRID:grid.413878.1) (ISNI:0000 0004 0572 9327) 
 National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Pathology, Tainan, Taiwan (GRID:grid.412040.3) (ISNI:0000 0004 0639 0054) 
 University of Texas Health Science Center, Department of Urology, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8) 
 University of Texas Health Science Center, Department of Pathology and Laboratory Medicine, San Antonio, USA (GRID:grid.468222.8) 
 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Department of Urology, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8) 
 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Department of Medicine, San Antonio, USA (GRID:grid.468222.8) 
 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Biobehavior Laboratory, School of Nursing, San Antonio, USA (GRID:grid.468222.8) 
 University of Texas Health Science Center, Department of Molecular Medicine, San Antonio, USA (GRID:grid.468222.8); University of Texas Health Science Center, Mays Cancer Center, San Antonio, USA (GRID:grid.468222.8) 
Pages
6569
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2878164059
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.